Bispecific Antibodies in Lymphoma - Another Win for T Cells
- PMID: 36507659
- DOI: 10.1056/NEJMe2212732
Bispecific Antibodies in Lymphoma - Another Win for T Cells
Comment on
-
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11. N Engl J Med. 2022. PMID: 36507690 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous